{"id":"NCT00388973","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder","officialTitle":"A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2006-10-17","resultsPosted":"2010-04-01","lastUpdate":"2010-04-01"},"enrollment":338,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Quetiapine","otherNames":[]}],"arms":[],"summary":"The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major depressive disorder.\n\nPLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9.","timeFrame":"Baseline to Week 9","effectByArm":[{"arm":"Quetiapine XR","deltaMin":-16,"sd":8},{"arm":"Placebo","deltaMin":-9,"sd":8}],"pValues":[]},"eligibility":{"minAge":"66 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":43,"countries":["United States","Argentina","Estonia","Finland","Russia","Ukraine"]},"refs":{"pmids":["24816198","24175720","24162081","23639212","23567397"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":166},"commonTop":["Headache","Dizziness","Somnolence","Dry Mouth"]}}